Poll: Americans avoid planning severe illness

“I’ll cope with it tomorrow. The perpetual tomorrow.”

That is what one individual told a pollster, encapsulating how Americans avoid preparing in advance for severe illness and dying.

While most Americans say it’s vital that you write lower their medical wishes in situation they become seriously ill, merely a third did so, based on the poll, released Thursday through the Kaiser Family Foundation. (Kaiser Health News is definitely an editorially independent program from the Kaiser Family Foundation.)

When adults with severe illness don’t write lower their wishes, family people tend to be less inclined to know precisely what their family member want, and also the adults are less inclined to feel their wishes are carefully adopted, the poll found.

The poll surveyed an agent sample of two,040 Americans by telephone, including 998 with direct experience with severe illness in the household.

Americans 65 and older tend to be more prepared than more youthful Americans but, still, only 58 percent for the reason that age bracket possess a written document outlining their medical wishes in situation of significant illness, and 67 percent have documented who they would like to make medical decisions on their own account when they become incapacitated, the poll found.

The very best reason people gave for staying away from these tasks is the fact that “there are extremely a number of other things to bother with at this time.Inches

The poll identifies variations across racial and ethnic groups:

Black adults 65 and older were much less likely than white-colored and Hispanic counterparts to possess written lower their medical wishes.

Black and Hispanic adults were much more likely than whites to cite “don’t wish to consider sickness and death” like a primary reason they didn’t document their wishes.

The poll also highlights challenges faced by seriously ill adults as well as their families. A seriously ill adult is understood to be someone 65 or older with a chronic condition, for example diabetes, bronchial asthma or cardiovascular disease, and has functional limitations, for example difficulty eating, dressing or while using toilet. The findings include:

  • About 50 % of adults with severe illness had trouble understanding instructions for medications and health care in the last year.
  • 1 in 5 family caregivers stated no-one can provide them with a rest when they require it.
  • In regards to a third of family caregivers stated they didn’t get any training regarding how to move their family member securely, recognize indications of discomfort or distress, or administer medications.

“The main one factor I’d say, in my family people, I could demonstrate to them how you can wash hair, how you can alter the bed using the part of it, individuals things,” one caregiver told pollsters. “But it could have been so useful when the hospital, community center, anybody, had offered some fundamental classes.”

KHN’s coverage of finish-of-existence and heavy illness issues is based on The Gordon and Gloria Moore Foundation.


Kaiser Health NewsThis short article was reprinted from khn.org with permission in the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is really a program from the Kaiser Family Foundation, a nonpartisan healthcare policy research organization unaffiliated with Kaiser Permanente.

UW study shows outcomes of toxic air and mental distress

There’s little debate within the outcomes of polluting of the environment and also the human respiratory system system: Studies have shown that dirty air can impair breathing and aggravate various lung illnesses. Other potential effects are now being investigated, too, as scientists examine connections between toxic air and weight problems, diabetes and dementia.

Now additionally list mental distress, which College of Washington scientific study has found can also be connected with polluting of the environment. The greater the amount of particulates in mid-air, the UW-brought study demonstrated, the higher the effect on mental health.

The research, printed within the November issue of Health & Place, is thought to be the first one to make use of a across the country representative survey pool, mix-referenced with pollution data in the census block level, to judge the bond between toxic air and mental health.

“This is actually aiming a brand new trajectory round the health results of polluting of the environment,Inch stated Anjum Hajat, a helper professor of epidemiology within the UW School of Public Health. “The results of polluting of the environment on cardiovascular health insurance and lung illnesses like bronchial asthma are very well established, however this section of brain health is really a newer section of research.”

In which a person lives can produce a huge difference to health and excellence of existence. Scientists have identified “social determinants” of mental and physical well-being, for example accessibility to well balanced meals at local grocers, use of nature or neighborhood safety.

Polluting of the environment, too, continues to be connected with behavior changes – being economical time outdoors, for example, or leading a far more sedentary lifestyle – that may be associated with mental distress or social isolation.

The UW study searched for an immediate link between toxic air and mental health, counting on some 6,000 respondents from the bigger, national, longitudinal study, the Panel Study of Earnings Dynamics. Researchers then merged an aura pollution database with records akin to the neighborhoods of each one of the 6,000 survey participants. They focused on measurements of proper particulate matter, an ingredient created by vehicle engines, fireplaces and wood stoves, and power plants fueled by coal or gas. Fine particulate matter (particles under 2.5 micrometers across) is definitely inhaled, could be made available to the blood stream and it is considered of and the higher chances than bigger particles. (To picture precisely how small fine particulate matter is, think about this: The typical real hair is 70 micrometers across.)

The present safety standard for fine particulates, based on the U.S. Ecological Protection Agency, is 12 micrograms per cubic meter. Between 1999 and 2011, the time period examined within the UW study, survey respondents resided in neighborhoods where fine particulates measured between 2.16 to 24.23 micrograms per cubic meter, by having an average degree of 11.34.

Laptop computer questions highly relevant to the UW study gauged participants’ feelings of sadness, nervousness, hopelessness and so on and were scored having a scale that assesses mental distress.

The UW study discovered that the chance of mental distress elevated alongside the quantity of fine particulate matter in mid-air. For instance, in areas rich in amounts of pollution (21 micrograms per cubic meter), mental distress scores were 17 % greater compared to areas with lower levels of pollution (5 micrograms per cubic meter). Another finding: Every rise in pollution of 5 micrograms per cubic meter had exactly the same effect like a 1.5-year reduction in education.

Researchers controlled for other physical, behavior and socioeconomic factors that may influence mental health, for example chronic health problems, unemployment and excessive consuming.

However, many patterns emerged that warrant more study, described primary author Victoria Sass, a graduate student within the Department of Sociology.

Once the data are damaged lower by race and gender, black men and white-colored women show the most important correlation between polluting of the environment and mental distress: The amount of distress among black men, for example, in regions of high pollution, is 34 percent more than those of white-colored men, and 55 percent more than those of Latino men. An obvious trend among white-colored women may be the substantial rise in distress — 39 percent — as pollution levels rise from low to high.

The key reason why polluting of the environment impacts mental health, especially among specific populations, was past the scope from the study, Sass stated. But that is why is further research important.

“Society is segregated and stratified, which places a pointless burden on some groups,” Sass stated. “Even moderate levels could be harmful to health.”

Polluting of the environment, however, is one thing that may be mitigated, Hajat stated, and it has been declining within the U . s . States. It is a health condition having a obvious, actionable solution. However it necessitates the political will to carry on to manage quality of air, Sass added.

“We should not consider this as being an issue that’s been solved,” she stated. “There’s a great deal to be stated for getting federal guidelines which are rigorously enforced and constantly updated. Ale communities to possess climate is going to be impacted with increased poor regulation.”

Source:

http://world wide web.washington.edu/

Without Funding, Countless Children Could Lose Healthcare Coverage From Nick Program

The Bronchial asthma and Allergy First step toward America (AAFA) supports a 5-year re-authorization of funding for that Children’s Medical Health Insurance Program (Nick) without offsetting cuts (pay-fors) with other programs that benefit children. Nick is really a bipartisan success story that needs to be celebrated. This program was produced in 1997 and it has been championed by lawmakers on sides from the aisle since its beginning. Along with State medicaid programs, Nick helps to lessen the amount of uninsured children with a outstanding 68 percent, using more than 95 % of children in the usa presently being signed up for some type of insurance policy. Nick presently provides high-quality, cost-effective coverage in excess of 8 million low-earnings American children and 370,000 women that are pregnant, and it should be ongoing. 

Regrettably, Congress unsuccessful to do something prior to the current funding for Nick expired in September. Which means that states will have to send disenrollment notices to battling families and determine methods to stretch their remaining federal dollars as lengthy as you possibly can. Some might be able to keep kids covered a couple of several weeks, while some have only a couple of days. 

Many studies have proven that Nick works. In Or, parents of Nick enrollees were more prone to report the youngster is at good or stable health after being signed up for this program for any year. In New You are able to, kids with special healthcare needs which were signed up for Nick experienced substantial enhancements in use of care: unmet needs for prescription drugs declined from 36 percent to 9 % one of the formerly uninsured and unmet needs for niche care declined 48 percent to 10 % for individuals formerly uninsured and 32 percent to two percent for individuals with mental/behavior conditions. 

Children signed up for Nick experience benefits that stretch beyond health. In California, children signed up for Nick shown “significant, sustained gains” within their ability to concentrate at school and in school activities. Children signed up for the Kansas Nick program for over a year missed less times of school due to injuries or illness. 

Families who depend on Nick already face uncertainty and challenges, whether building a complicated health problem for his or her child or figuring out how you can afford day-to-day bills. The final factor these families require is added uncertainty about the way forward for their children’s dental and medical coverage or if they’re going to have ongoing use of necessary prenatal care services. 

What else could you do in order to help get Nick within the finish line? Achieve to your governors and condition legislators and keep these things speak to your congressional delegation about Nick. Call your member offices today and get them about Nick. Let them know you need to visit a bipartisan agreement and also you need it passed soon. Motivate people who aren’t around the committees of jurisdiction to defend Nick and youngsters. 

Remember, Nick is an extremely popular, bipartisan, lengthy-standing program which has done the job it required to provide for over twenty years. Children are covered now in a greater rate than in the past. We can’t return.

Use our tool below to inform your senator to support a 5-year extension of Nick. Our tool enables you to definitely send an e-mail, publish your message on Facebook and/or call your senator. To speak to your senator, stick to the steps below:

AAFA’s Action Alerts inform advocates about pending federal or condition bronchial asthma and allergy legislation. Whenever you register being an AAFA advocate, you will get email alerts on national or condition issues. Together with your help, the largest a positive change within the lives of individuals impacted by bronchial asthma and allergic reactions.

JOIN NOW

Azithromycin is Overprescribed for Childhood Pneumonia

Azithromycin, probably the most generally used antibiotics in pediatrics, was prescribed to 12.two million outpatients in 2013 and taken into account almost 20 % of antibiotic prescriptions for kids within the U. S. ambulatory setting, based on a current research in the Vanderbilt College Clinic.

A mix of two antibiotics is frequently prescribed to deal with community-acquired pneumonia in youngsters however the study implies that using one of the 2 has got the same help to patients generally. Based on these studies finding, amoxicillin alone, instead of coupled with azithromycin, is equally as effective and a better option as it requires efforts to curb antibiotic resistance.

‘Amoxicillin alone, instead of coupled with azithromycin, is equally as effective and a better option as it requires efforts to curb antibiotic resistance.’

“Combination therapy with azithromycin is unnecessary generally of pediatric pneumonia, both since the bacteria targeted by azithromycin are less frequent than other reasons for pneumonia, including infections, and the potency of azithromycin is not clearly shown in prior studies,” stated lead author Derek Johnson, M.D., Miles per hour, assistant professor of Pediatrics.

Advertisement

“By minimizing antibiotic exposure whenever you can, we are able to preserve the potency of presently available antibiotics.”

Johnson and co-authors studied 1418 children (693 women and 725 boys) hospitalized for radiologically confirmed community-acquired pneumonia. Amoxicillin, a beta-lactam antibiotic, was utilized on 72 percent from the study patients while 28 percent received a mix of amoxicillin plus azithromycin.

There have been no significant variations long of stay, intensive care admission, readmissions or recovery at follow-up between your groups. Thus, “the combined therapy demonstrated no benefit within the single therapy of just amoxicillin,” Johnson stated.

There have been also no variations among important subgroups of kids probably to take advantage of the combination therapy, including kids with Mycoplasma pneumoniae, individuals with wheezing and individuals accepted to intensive care, he added.

“Amoxicillin or even the IV equivalent, ampicillin, treat the most typical bacteria that create pneumonia and therefore are suggested by national guidelines as treating option for most kids with pneumonia,” Johnson stated.

“Azithromycin can be used to deal with so known as atypical pneumonia bacteria, including Mycoplasma pneumoniae. Atypical infections are somewhat common in older kids and adolescents, but the advantages of treating these infections is less obvious.”

Additional research to recognize which kids with pneumonia will benefit from macrolide antibiotics like azithromycin is urgently needed, Johnson stated.

“Pneumonia makes up about more antibiotic days in U.S. children’s hospitals than every other condition. It’s a hugely important target for antimicrobial stewardship efforts,” he stated. “Reducing unnecessary antibiotic use within pediatric pneumonia along with other respiratory system illnesses is a technique to help slow the advancement of antimicrobial resistance.”

In many pneumonia cases, the particular causative pathogens might be hard to identify, and antibiotics are selected empirically. Although about 30 % of kids hospitalized with pneumonia received combination therapy within this study, atypical pathogens were detected in under 9 %.

“This apparent discrepancy highlights the difficulties of empirical therapy for pediatric pneumonia, and the necessity to characterize the most typical pneumonia pathogens and the potency of antibiotic regimens, to tell empirical treatment”, stated Carlos G. Grijalva, M.D., Miles per hour, senior author and affiliate professor of Health Policy.

Co-author Kathryn Edwards, M.D., professor of Pediatrics and also the Sarah H. Sell and Cornelius Vanderbilt Chair, stated the report belongs to a really large study of pneumonia in adults and children conducted at Vanderbilt and sites in Utah, Chicago and Memphis.

“The work has revealed the key role of infections in pneumonia and provided assistance with the very best antibiotics to make use of to deal with microbial pneumonia,” she stated.

The entire research report can be obtained at JAMA Pediatrics.

Source: Eurekalert

Advertisement

Dupilumab Shows Benefit for Those With Severe Asthma During Clinical Trial

The Asthma and Allergy Foundation of America is sharing this press release from the Regeneron Pharmaceuticals, Inc. and Sanofi to bring you the latest research news quickly.


[PRESS RELEASE]

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

Pivotal program is first with a biologic to show consistent reductions in asthma attacks and improvements in lung function across a broad population of uncontrolled asthma patients

TARRYTOWN, N.Y. and PARIS, Oct. 31, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints. For the primary endpoint, at 24 weeks in the overall population, dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70 percent on average (median reduction of 100 percent) compared to 42 percent with placebo (median reduction of 50 percent) (p less than 0.0001). In prespecified analyses of patients with baseline eosinophil counts greater than or equal to 300 cells/microliter, adding dupilumab significantly reduced OCS use by 80 percent on average (median reduction of 100 percent) compared to 43 percent for placebo (median reduction of 50 percent) (nominal p equals 0.0001).

At 24 weeks, despite the reduced use of OCS, patients treated with dupilumab had 59 percent fewer attacks (exacerbations) in the overall population (p less than 0.0001) and 71 percent fewer attacks in patients with eosinophil counts greater than or equal to 300 cells/microliter. Also at 24 weeks, compared to placebo, dupilumab improved lung function, as assessed by forced expiratory volume over one second (FEV1) by 220ml (15 percent) in the overall population (p equals 0.0007) and by 320ml (25 percent) in patients with eosinophil counts greater than or equal to 300 cells/microliter (nominal p equals 0.0049).

“This Phase 3 study showed that most severe asthma patients could substantially reduce their dependence on oral corticosteroids, with half completely eliminating their use of oral corticosteroids, which are not recommended for long-term use and can carry significant and potentially irreversible safety risks. Importantly, despite a reduction in oral corticosteroid use, dupilumab was associated with an improvement in lung function. This is the third study in which dupilumab has demonstrated a reduction in asthma attacks and improvement in lung function in a broad group of patients with uncontrolled asthma – this effect was most profound in patients with elevated markers of Type 2 allergic inflammation, such as an eosinophil count over 300,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “Dupilumab blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation. We remain committed to investigating dupilumab in other Type 2 inflammatory diseases including eosinophilic esophagitis, nasal polyps, pediatric atopic dermatitis and food allergy.”

“This Phase 3 study enrolled severe steroid-dependent asthma patients regardless of eosinophil levels or other biomarkers at baseline, and the results showed improvements compared to placebo on lung function and exacerbations across patient subgroups – those with baseline eosinophil counts above 300 cells/microliter, above 150 cells/microliter and below 150 cells/microliter,” said Elias Zerhouni, M.D., President, Global R&D, Sanofi. “It is striking that dupilumab has demonstrated a consistent improvement in lung function across the asthma program as this is critically important for patients with severe asthma struggling with declines in their everyday breathing ability.”

The safety and tolerability profile of dupilumab in this study was consistent with previous studies. There were more dupilumab-treated patients with injection site reactions (9 percent dupilumab vs. 4 percent placebo). There were more dupilumab-treated patients with an increase in eosinophil counts (14 percent dupilumab vs. 1 percent placebo), most of which were mild and the vast majority of which resolved. The overall rates of adverse events, including infections, conjunctivitis, and herpes were comparable between the dupilumab and placebo groups.

Patients with severe chronic asthma live with a profound decrease in their lung function, approximately 52 percent of predicted normal for those in this study at baseline, which impacts their ability to breathe normally, and may lead to frequent exacerbations that require acute treatment and hospitalization. These problems occur even in patients who are treated with chronic OCS to manage their symptoms.

In the Phase 3 study, known as LIBERTY ASTHMA VENTURE, additional secondary endpoint results at 24 weeks included the following:

  • In the overall population, 80 percent of patients who received dupilumab reduced their OCS dose by at least half while maintaining overall asthma control compared to 50 percent of patients who received placebo (p less than 0.0001). In patients with eosinophil counts greater than or equal to 300 cells/microliter (high EOS), dupilumab allowed for a reduction in the OCS dose by at least half in 88 percent of patients compared to 52 percent for placebo (nominal p equals 0.0011).
  • In the overall population, 69 percent of patients who received dupilumab reduced their OCS dose to less than 5 mg per day while maintaining asthma control compared to 33 percent of patients who received placebo (p less than 0.0001); in the high EOS group, 84 percent of dupilumab patients reduced their OCS dose to less than 5 mg per day compared to 40 percent for placebo (nominal p equals 0.0002).

“Severe, uncontrolled asthma can lead to a dependence on oral corticosteroids, with systemic steroid exposure potentially leading to serious short- and long-term adverse effects, including weight gain, diabetes, osteoporosis, glaucoma, anxiety, depression, cardiovascular disease and immunosuppression,” said Professor Mario Castro, M.D., MPH, FCCP, Washington University School of Medicine in St. Louis. “There is an urgent need for new therapies that can decrease or eliminate chronic oral corticosteroid use, as well as reduce severe asthma attacks and improve lung function in this difficult-to-treat patient population.”

The VENTURE study enrolled 210 patients (103 in the dupilumab group and 107 in the placebo group) with severe asthma and regular use of maintenance OCS in the six months prior to enrollment in the study. In the study, the prescribed OCS was prednisone or prednisolone. Patients were randomized using a 1:1 ratio and treated with either dupilumab (300 mg every other week with a loading dose of 600 mg) or placebo. The median baseline eosinophil count in the study was 260 eosinophils/microliter.

Detailed results from this study will be submitted for presentation at a future medical congress. VENTURE is the third trial in the uncontrolled persistent asthma pivotal clinical program and follows positive results from the Phase 3 QUEST study and Phase 2b pivotal study of dupilumab. The companies plan to submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) by the end of this year. Also included in the LIBERTY ASTHMA clinical development program is the TRAVERSE trial, a long-term safety extension study. The potential use of dupilumab in asthma is currently under clinical development and the safety and efficacy have not been fully evaluated by any regulatory authority.

In March 2017, the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) in the U.S. for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies. The European Commission (EC) also granted marketing authorization for Dupixent for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy in September 2017.

About Uncontrolled Persistent Asthma
People who live with uncontrolled, persistent asthma often experience decreased lung function and have severe attacks (exacerbations) that may lead to emergency room visits or hospitalizations. Despite currently available treatments, there is a need for new medicines that offer comprehensive asthma control including preservation of lung function and reduction in exacerbations. Uncontrolled, persistent asthma is often associated with other Type 2 allergic inflammatory diseases including atopic dermatitis, nasal polyps, allergic rhinitis, eosinophilic esophagitis and food allergies. The disease is characterized by an imbalance or over activity of certain immune cells (including eosinophils) and signaling proteins known as interleukins. Two of these are interleukin-4 (IL-4) and interleukin-13 (IL-13), which are central drivers of Type 2 inflammation.

About Dupilumab 
Dupilumab is a fully human monoclonal antibody that is designed to simultaneously inhibit overactive signaling of IL-4 and IL-13 cytokines. Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases that are driven by Type 2 inflammation, including pediatric atopic dermatitis (Phase 3), nasal polyps (Phase 3) and eosinophilic esophagitis (Phase 2). These potential uses are investigational and the safety and efficacy have not been evaluated by any regulatory authority. Dupilumab was discovered using Regeneron’s proprietary VelocImmune®technology that yields optimized fully-human antibodies, and is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

For more information on dupilumab clinical trials please visit www.clinicaltrials.gov.

IMPORTANT SAFETY INFORMATION 

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.   
Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

  • have eye problems
  • have a parasitic (helminth) infection
  • have asthma
  • are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with DUPIXENT.
  • are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. 
  • are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. If you have asthma and are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider. 

DUPIXENT can cause serious side effects, including:

  • Allergic reactions. Stop using DUPIXENT and go to the nearest hospital emergency room if you get any of the following symptoms: fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, or skin rash.
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.

The most common side effects include injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips. 

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed. If your healthcare provider decides that you or a caregiver can give DUPIXENT injections, you or your caregiver should receive training on the right way to prepare and inject DUPIXENT. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider. 

Please click here for the full Prescribing Information. The patient information is available here.

INDICATION

DUPIXENT is used to treat adult patients with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children. DUPIXENT is administered by subcutaneous injection every two weeks after an initial loading dose.

About Sanofi 
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for the past 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully human antibodies, and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter. 

Sanofi Contacts:
Media Relations
Ashleigh Koss 
Tel: +1 908 981 8745
[email protected]

Regeneron Contacts:
Media Relation
Arleen Goldenberg
Tel: +1 (914) 847-3456
Mobile: +1 (914) 260-8788
[email protected]

It is important to stay up-to-date on news about asthma and allergies. By joining our community and following our blog, you will receive news about research and treatments. Our community also provides an opportunity to connect with other patients who manage these conditions for support.

JOIN NOW